多药耐药结核病项目中高剂量利福平、异烟肼和吡嗪酰胺治疗的中敏剂量依赖性折点
该研究采用蒙特卡洛实验进行目标达成分析,评估在10000例结核患者中提高利福平、异烟肼和吡嗪酰胺剂量能否使抑菌浓度介于拟议折点与传统折点之间的细菌达到PK/PD目标。结果显示异烟肼900 mg/日、利福平1800 mg/日、吡嗪酰胺4 g/日可界定新的中敏剂量依赖性范围,基于MIC分布分别有93%、78%、27%的分离株处于该范围。作者认为在2个浓度进行药敏试验并据此使用更高剂量可避免换用毒性更大的二线治疗,但需确证性临床研究。
要点
- 异烟肼900 mg/日对应的中敏剂量依赖性MIC范围为0.0312-0.25 mg/L,MIC≥0.5 mg/L为耐药。
- 利福平1800 mg/日对应的中敏剂量依赖性MIC范围为0.0625-0.25 mg/L,MIC≥0.5 mg/L为耐药。
- 吡嗪酰胺4 g/日对应的中敏剂量依赖性MIC范围为37.5-50 mg/L,MIC≥100 mg/L为耐药。
核心结论
- 在2个界定中敏剂量依赖性范围的浓度进行药敏试验并随后使用更高剂量,可能避免换用毒性更大的二线治疗。
- 确证性临床研究将为改变治疗指南提供证据。
研究设计与样本
- 采用蒙特卡洛实验进行目标达成研究,评估在10000例结核患者中提高利福平、异烟肼和吡嗪酰胺剂量能否使抑菌浓度介于拟议折点与传统折点之间的细菌达到PK/PD目标。
主要发现
- 异烟肼900 mg/日界定的新中敏剂量依赖性MIC范围为0.0312-0.25 mg/L,MIC≥0.5 mg/L为耐药。
- 利福平1800 mg/日对应的中敏剂量依赖性MIC范围为0.0625-0.25 mg/L,MIC≥0.5 mg/L为耐药。
- 吡嗪酰胺4 g/日对应的中敏剂量依赖性MIC范围为37.5-50 mg/L,MIC≥100 mg/L为耐药。
- 基于MIC分布,处于中敏剂量依赖性范围的分离株比例分别为异烟肼93%、利福平78%、吡嗪酰胺27%。
关键数值与推荐
- 异烟肼、利福平和吡嗪酰胺的PK/PD目标暴露折点分别为0.0312 mg/L、0.0625 mg/L和50 mg/L,已在临床研究中得到确认。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacterial susceptibility is categorized as susceptible, intermediate-susceptible dose-dependent (ISDD), and resistant. The strategy is to use higher doses of first-line agents in the ISDD category, thereby preserving the use of these drugs. This system has not been applied to antituberculosis drugs. Pharmacokinetic/pharmacodynamic (PK/PD) target exposures, in tandem with Monte Carlo experiments, recently identified susceptibility breakpoints of 0.0312 mg/L for isoniazid, 0.0625 mg/L for rifampin, and 50 mg/L for pyrazinamide. These have been confirmed in clinical studies. METHODS: Target attainment studies were carried out using Monte Carlo experiments to investigate whether rifampin, isoniazid, and pyrazinamide dose increases would achieve the PK/PD target in >90% of 10000 patients with tuberculosis caused by bacteria, revealing minimum inhibitory concentrations (MICs) between the proposed and the traditional breakpoints. RESULTS: We found that an isoniazid dose of 900 mg/day identified a new ISDD MIC range of 0.0312-0.25 mg/L and resistance at MIC ≥0.5 mg/L. Rifampin 1800 mg/day would result in an ISDD of 0.0625-0.25 mg/L and resistance at MIC ≥0.5 mg/L. At a dose of pyrazinamide 4 g/day, the ISDD MIC range was 37.5-50 mg/L and resistance at MIC ≥100 mg/L. Based on MIC distributions, 93% (isoniazid), 78% (rifampin), and 27% (pyrazinamide) of isolates would be within the ISDD range. CONCLUSIONS: Drug susceptibility testing at 2 concentrations delineating the ISDD range, and subsequently using higher doses, could prevent switching to a more toxic second-line treatment. Confirmatory clinical studies would provide evidence to change treatment guidelines.
引用
- Zuur MA, Pasipanodya JG, van Soolingen D, et al. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. Clin Infect Dis. 2018. PMID: 29697766. doi:10.1093/cid/ciy346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。